Clinical Trials Browser

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT03297606 2026-03-27

CAPTUR

Phase 2 Recruiting

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07371585 2026-03-27

TOP-REAL

Phase 2 Recruiting

300 enrolled

Breast

Breast Neoplasms

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

Phase 2 Recruiting

125 enrolled

Breast

Breast Neoplasms

NCT05325632 2026-03-02

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

Phase 2 Recruiting

53 enrolled

Breast

Breast Neoplasms

NCT07053085 2026-02-27

A Study of Surgery and Radiotherapy in People With Breast Cancer

Phase 2 Recruiting

162 enrolled

Breast

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Phase 2 Recruiting

74 enrolled

Breast

Breast Neoplasms

NCT07393425 2026-02-06

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

Phase 2 Recruiting

50 enrolled

Breast

Breast Neoplasms

NCT07340398 2026-01-21

TAYLOR

Phase 2 Recruiting

200 enrolled

Breast

HER2-positive Early Breast Cancer

NCT04329065 2025-11-06

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Phase 2 Recruiting

25 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT06178159 2025-10-01

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms

NCT05900206 2025-09-02

ARIADNE

Phase 2 Recruiting

370 enrolled

Breast

Breast Neoplasms

NCT05582499 2025-08-22

FASCINATE-N

Phase 2 Recruiting

716 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06445400 2025-08-03

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Phase 2 Recruiting

120 enrolled

Breast

HER2-positive Breast Cancer

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

300 enrolled

Tumor-Agnostic

Neoplasms

NCT06441890 2025-07-14

BRE-10

Phase 2 Recruiting

28 enrolled

Breast

Breast Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Phase 2 Recruiting

180 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms

NCT04680442 2025-04-06

SCHOLAR-2

Phase 2 Recruiting

130 enrolled

Breast

Breast Neoplasms, Heart Failure

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

Phase 2 Recruiting

240 enrolled

Breast

Breast Neoplasms

NCT05020860 2025-02-27

RESPONSE

Phase 2 Recruiting

185 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05891561 2024-11-27

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Phase 2 Recruiting

120 enrolled

Breast

Breast Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05978648 2023-11-30

SMA-BC-002

Phase 2 Recruiting

116 enrolled

Breast

Breast Neoplasms

NCT05638594 2023-03-20

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

Phase 2 Recruiting

236 enrolled

Breast

Breast Neoplasms

NCT04993014 2021-08-06

HER2Cell

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms, Neoplastic Cells, Circulating

Clinical Trials

TAPUR

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

CAPTUR

TOP-REAL

ctDNA in HER2+ EBC Neoadjuvant Treatment

I-SPY

EmpowHER 208

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

A Study of Surgery and Radiotherapy in People With Breast Cancer

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer

TAYLOR

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

ARIADNE

FASCINATE-N

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

ProTarget

BRE-10

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

SCHOLAR-2

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

RESPONSE

Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

DRUP

SMA-BC-002

Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

HER2Cell